Ashwani Koul

Ashwani Koul

Auto-generated profile, based on publicly available information

Ashwani Koul

Panjab University

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBSushma Bharrhan
Sushma Bharrhan
AKAshwani Koul
Ashwani Koul
KCKanwaljit Chopra
Kanwaljit Chopra
PRPraveen Rishi
Praveen Rishi
Induction of nuclear factor kappa B (NF-κB)-mediated gene expression has been implicated in the pathogenesis of alcoholic liver disease through enhanced production of reactive oxygen species and pro-inflammatory mediators. The present study was carried out to investigate the role of catechin as a chain breaking inhibitor against experimental alcoholic liver injury. Rats were administered 35% v/v ethanol orally at a dose of 10 g/Kg/day for two weeks, followed by 14 g/Kg/day for 10 weeks. Catechin (50 mg/Kg) was co-supplemented after 4 weeks of alcohol treatment till the end of the dosing period. Following chronic alcohol exposure, rats developed endotoxemia and severe pathological changes in the liver such as pronounced fatty change, vacuolar degeneration and inflammation. These changes were accompanied by activation of NF-κB and induction of inflammatory and cytotoxic mediators leading to increased level of tumor necrosis factor-alpha, enhanced formation of malondialdehyde in the liver followed by drastic alterations in the hepatic antioxidant defense systems. Additionally, nitrite levels and lactate dehydrogenase activities were also significantly elevated on chronic alcohol consumption. Alcohol exposure also increased the number of micronucleated cells indicating that alcohol abuse may again be associated with the nuclear changes. Supplementation with catechin ameliorated the alcohol-induced liver injury by downregulating the endotoxin-mediated activation of initial signalling molecule NF-κB and further going downstream the signalling cascade including tumor necrosis factor-alpha, nitric oxide and reactive oxygen species and by enhancing the antioxidant profile. These observations correlated well with the histological findings. Moreover, a remarkable decrease in the percentage of micronucleated cells was observed with catechin supplementation indicating an apparent protection against alcohol-induced toxicity. These findings suggest that catechin may alleviate experimental alcoholic liver disease by suppressing induction of NF-κB, a key component of signalling pathway, thus forming a pharmacological basis for designing novel therapeutic agents against alcohol induced endotoxin-mediated liver injury.

23 August 2010 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
NAN. Arora
N. Arora
AKA. Koul
A. Koul
MBM. P. Bansal
M. P. Bansal

9 October 2015 in Nutrition and Cancer
Verified
Journal Article
Closed access
NBNisha Bhatia
Nisha Bhatia
PGPrachi Gupta
Prachi Gupta
BSBaljinder Singh
Baljinder Singh
AKAshwani Koul
Ashwani Koul
Targeting altered pathways during initial stage of hepatocellular carcinoma (HCC) development is viewed as an effective and promising strategy to control this disease. Present study investigated the potential effect of lycopene-enriched tomato extract (LycT) on hypoxia-induced factor (HIF)-1α, HOX, VEGF, CD31, matrix metalloproteinase (MMP)-2, MMP-9, and alpha fetoprotein (AFP)expression during initial stages of N-nitrosodiethylamine (NDEA) induced HCC. Female Balb/c mice (8–10 wk) were assigned to 4 groups: control, NDEA (200 mg NDEA i.p./kg body weight, cumulative), LycT (5 mg lycopene orally/kg body weight; 3 times a week), and LycT + NDEA. LycT treatment began 2 wk before NDEA administration and continued until the end of the 10 wk study. The onset of HCC by NDEA was associated with significant alteration in serum biochemical markers [alanine transaminases (ALT), aspartate transaminases (AST), and alkaline phosphatases (ALP), lactate dehydrogenase (LDH), urea, A/G ratio, and bilirubin] and in liver histopathology. LycT treatment significantly reduced the levels of these markers. LycT treatment to NDEA mice also led to significant reduction in protein levels of AFP, HIF-1α, VEGF, CD31, MMP-2, and MMP-9 in comparison with NDEA group alone. These parameters are important biomarkers of hypoxia, angiogenesis, and metastasis, which reflect the advanced disease stage. The study provides evidence that prophylactic dietary supplementation with LycT may counteract HCC progression and/or protect against disease onset.

1 February 2006 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
AKAshwani Koul
Ashwani Koul
NMNupur Mukherjee
Nupur Mukherjee
SGSubhash Chander Gangar
Subhash Chander Gangar

1 June 2018 in Integrative Medicine Research
Verified
Journal Article
Open access
NCNeha Arora Chugh
Neha Arora Chugh
SBShreya Bali
Shreya Bali
AKAshwani Koul
Ashwani Koul
The use of botanicals for maintaining good health and preventing diseases is undisputed. The claimed health benefits of natural health products and herbal medicines are based on traditional claims, positive results obtained in preclinical studies and early phase clinical trials that are not backed by safety and efficacy evidences approved by regulatory agencies. Although, the popularity of botanicals is growing, health care practitioners of modern medicine seldom recommend their use because of ill equipped database of their safety and potency. This review discusses problems that preclude botanicals from integrating into the mainstream contemporary therapeutics and cues that provide impetus for their realisation.

1 May 2017 in Frontiers in Medicine
Verified
Journal Article
Open access
SSSarika Sharma
Sarika Sharma
BSBaljinder Singh
Baljinder Singh
AKAshwani Koul
Ashwani Koul
BMBhagwant Rai Mittal
Bhagwant Rai Mittal
Introduction: The aim of the present study was to compare the therapeutic efficacy of 153SmEDTMP and 177LuEDTMP in pain palliation in cancer patients with skeletal metastases. Materials and methods: Thirty patients (25 M: 5 F, mean age: 66.0 ± 14.7 years) of breast/prostate cancer with documented skeletal metastases were recruited prospectively. Twenty patients were considered randomly for treatment with 153Sm-EDTMP and 10 patients with 177Lu-EDTMP respectively. Using fixed dose of 37.0 MBq/Kg. body weight of each, the mean administered doses of 153Sm-EDTMP and 177Lu-EDTMP were 2155.2 ± 419.6 MBq (1347.0 -2857.0) and 1935.1 ± 559.4 MBq (1073.0-2627.0) respectively. Anterior and posterior whole body images were acquired at different time points following radioactivity administration. The first data set of pre-void images (acquired at 0.5h) representing the total activity of either of 153Sm-EDTMP or 177Lu-EDTMP was considered as reference images. All the serial images were used for patients’ dosimetry analysis by using OLINDA algorithm. Reduction in pain scoring was assessed clinically over 8 –weeks by using appropriate WHO criteria and correlated with the absorbed dose to the metastatic sites. Results: A total of 86 metastatic lesions clearly visualized on post therapy serial images (matching on bone scans) were evaluated for absorbed dose calculations. Both 153Sm-EDTMP and 177Lu-EDTMP delivered similar absorbed dose to the metastatic sites i.e. 6.22 ± 4.21 mSv/MBq and 6.92 ± 3.92 mSv/MBq respectively. The mean absorbed doses to various other organs were found to be comparable and within the safe limits. A complete response for each radionuclide was evaluated as 80.0 %. No significant alternation in blood parameters and no untoward reaction was observed. However, a mild to severe toxicity was observed in 2 patients (1 each with 153Sm-EDTMP and 177Lu-EDTMP). Kaplan-Meier survival analysis demonstrated that 27/30 patients had pain free survival (complete response) up to the observational period of 8 weeks. However, no statistically significant correlation could be established between the pain scoring and absorbed dose to metastatic sites. Conclusion: Both the radionuclides thus offer an effective and comparable therapeutic efficacy for bone pain palliation at an affordable cost and can be used interchangeably as per the availability.